DBV Technologies S.A. (EPA:DBV)
3.765
+0.045 (1.21%)
Mar 6, 2026, 5:35 PM CET
DBV Technologies Revenue
DBV Technologies had revenue of $2.77M USD in the quarter ending September 30, 2025, with 158.77% growth. This brings the company's revenue in the last twelve months to $5.50M, down -56.04% year-over-year. In the year 2024, DBV Technologies had annual revenue of $4.15M, down -73.61%.
Revenue (ttm)
$5.50M
Revenue Growth
-56.04%
P/S Ratio
220.72
Revenue / Employee
$47.03K
Employees
117
Market Cap
1.04B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.15M | -11.58M | -73.61% |
| Dec 31, 2023 | 15.73M | 10.88M | 224.69% |
| Dec 31, 2022 | 4.84M | -864.00K | -15.14% |
| Dec 31, 2021 | 5.71M | -5.57M | -49.38% |
| Dec 31, 2020 | 11.28M | -3.43M | -23.33% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Inventiva | 16.97M |
| Nanobiotix | 10.16M |
| Valneva SE | 179.91M |
| MedinCell | 32.44M |
| Genfit | 45.13M |
| Transgene | 7.58M |
| Cellectis | 70.36M |
| ABIVAX Société Anonyme | 5.31M |
DBV Technologies News
- 1 day ago - DBV Technologies S.A. (DBVT) Presents at American Academy of Allergy, Asthma & Immunology (AAAAI) 2026 Annual Meeting - Slideshow - Seeking Alpha
- 1 day ago - DBV Technologies to Participate in Upcoming March Investor Conferences - GlobeNewsWire
- 4 days ago - DBV Technologies Peanut Patch Meets Primary Endpoint In Phase 3 VITESSE Study - Nasdaq
- 5 days ago - DBVT Shares Promising Phase 3 Trial Results for Viaskin Peanut - GuruFocus
- 5 days ago - DBV Technologies S.A.: DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting - Finanz Nachrichten
- 5 days ago - DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting - GlobeNewsWire
- 23 days ago - DBV Technologies To Present Additional VITESSE Phase 3 Data In Peanut-Allergic Children - Nasdaq
- 23 days ago - DBV Technologies S.A.: DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting - Finanz Nachrichten